Evidence map›Paper›PMID 37746202›Full record

ReviewFrontiers in fungal biology2022

Fluconazole-resistant

Pilar Escribano, Jesús Guinea

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in fungal biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Outcomes byAntimicrobial agents and chemotherapy · 2024
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Six-month surveillance ofFrontiers in cellular and infection microbiology · 2026
    Article
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Nine-Year Surveillance ofJournal of fungi (Basel, Switzerland) · 2025
    Article
  19. Article
  20. Clinical impact of fluconazole-resistantFuture microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Pilar EscribanoClinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Jesús GuineaClinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESHospital General Universitario Gregorio Marañón · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Candida parapsilosisERG11fluconazoleG458SK128NK143RresistanceY132F

Identifiers

PMID37746202
PMCPMC10512360
OpenAlexW4307271911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.